Mark Rothera - Net Worth and Insider Trading
Mark Rothera Net Worth
The estimated net worth of Mark Rothera is at least $653,065 dollars as of 2024-12-01. Mark Rothera is the Chief Commercial Officer of PTC Therapeutics Inc and owns about 14,341 shares of PTC Therapeutics Inc (PTCT) stock worth over $629,283. Mark Rothera is the President and CEO of Viracta Therapeutics Inc and owns about 100,000 shares of Viracta Therapeutics Inc (VIRX) stock worth over $14,300. Mark Rothera is also the Global President of Aegerion Pharmaceuticals Inc and owns about 4,813 shares of Aegerion Pharmaceuticals Inc (AEGR) stock worth over $9,482. Details can be seen in Mark Rothera's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mark Rothera has not made any transactions after 2023-12-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Mark Rothera
Mark Rothera Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark Rothera owns 4 companies in total, including Orchard Therapeutics PLC (ORTX) , PTC Therapeutics Inc (PTCT) , and Aegerion Pharmaceuticals Inc (AEGR) among others .
Click here to see the complete history of Mark Rothera’s form 4 insider trades.
Insider Ownership Summary of Mark Rothera
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ORTX | Orchard Therapeutics PLC | 2020-01-01 | director & See Remarks |
| PTCT | PTC Therapeutics Inc | 2017-01-03 | Chief Commercial Officer |
| AEGR | Aegerion Pharmaceuticals Inc | 2012-05-01 | Global President |
 | | 2023-12-01 | director & President and CEO |
Mark Rothera Latest Holdings Summary
Mark Rothera currently owns a total of 3 stocks. Among these stocks, Mark Rothera owns 14,341 shares of PTC Therapeutics Inc (PTCT) as of March 3, 2016, with a value of $629,283 and a weighting of 96.36%. Mark Rothera owns 100,000 shares of Viracta Therapeutics Inc (VIRX) as of December 1, 2023, with a value of $14,300 and a weighting of 2.19%. Mark Rothera also owns 4,813 shares of Aegerion Pharmaceuticals Inc (AEGR) as of April 30, 2012, with a value of $9,482 and a weighting of 1.45%.
Latest Holdings of Mark Rothera
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PTCT | PTC Therapeutics Inc | 2016-03-03 | 14,341 | 43.88 | 629,283 |
| VIRX | Viracta Therapeutics Inc | 2023-12-01 | 100,000 | 0.14 | 14,300 |
| AEGR | Aegerion Pharmaceuticals Inc | 2012-04-30 | 4,813 | 1.97 | 9,482 |
Holding Weightings of Mark Rothera
Mark Rothera Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark Rothera has made a total of 0 transactions in PTC Therapeutics Inc (PTCT) over the past 5 years. The most-recent trade in PTC Therapeutics Inc is the acquisition of 2,000 shares on March 3, 2016, which cost Mark Rothera around $12,460.
According to the SEC Form 4 filings, Mark Rothera has made a total of 1 transactions in Viracta Therapeutics Inc (VIRX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Viracta Therapeutics Inc is the acquisition of 100,000 shares on December 1, 2023, which cost Mark Rothera around $49,000.
According to the SEC Form 4 filings, Mark Rothera has made a total of 0 transactions in Aegerion Pharmaceuticals Inc (AEGR) over the past 5 years. The most-recent trade in Aegerion Pharmaceuticals Inc is the sale of 0 shares on April 30, 2012, which brought Mark Rothera around $0.
Insider Trading History of Mark Rothera
- 1
Mark Rothera Trading Performance
GuruFocus tracks the stock performance after each of Mark Rothera's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Rothera is 45.35%. GuruFocus also compares Mark Rothera's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Rothera within 3 months outperforms 3 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark Rothera's insider trading performs compared to the benchmark.
Performance of Mark Rothera
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 6.47 | | | | | |
| Relative Return to S&P 500(%) | 1.72 | | | | | |
Mark Rothera Ownership Network
Mark Rothera Owned Company Details
What does Orchard Therapeutics PLC do?
Who are the key executives at Orchard Therapeutics PLC?
Mark Rothera is the director & See Remarks of Orchard Therapeutics PLC. Other key executives at Orchard Therapeutics PLC include director & See Remarks Bobby Gaspar , 10 percent owner & other: See Remark 1 Fmr Llc , and 10 percent owner Ra Capital Healthcare Fund Lp .
Orchard Therapeutics PLC (ORTX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Orchard Therapeutics PLC (ORTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Orchard Therapeutics PLC (ORTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Orchard Therapeutics PLC (ORTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Orchard Therapeutics PLC Insider Transactions
Mark Rothera Mailing Address
Above is the net worth, insider trading, and ownership report for Mark Rothera. You might contact Mark Rothera via mailing address: C/o Aegerion Pharmaceuticals, Inc., 101 Main Street, Suite 1850, Cambridge Ma 02142.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
